Miyawaki, T., Shukuya, T., Sakamaki, K., Takahashi, T., Matsuda, S., Tanaka, K., Akamatsu, H., Sato, Y., Takahama, T., Aiba, T., Masuda, T., Furuya, N., Yokoyama, T., Tachihara, M., Okamoto, I., Kenmotsu, H., Yamamoto, N. (2026). Randomized phase II study of amivantamab + lazertinib versus afatinib in patients with uncommon/compound
                    <i>EGFR</i>
                    -mutated non-small cell lung cancer (WJOG17323L: AGEHA study).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps8676